Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Micron Technology, Inc. (MU) vs Smith & Nephew plc (SNN) Price & Performance

Micron Technology, Inc.Trade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Micron Technology, Inc. vs Smith & Nephew plc — how do they compare? Micron Technology, Inc. trades at $929.93 (market cap $980.90B), while Smith & Nephew plc trades at $29.75 (market cap $12.54B). The key difference: Micron Technology, Inc. is far larger — about 78.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.

MUSNN
Market Cap
$980.90B$12.54B
Sector
TechnologyHealth
52-Week High
$1.21K$38.70
52-Week Low
$115.79$28.73
Enterprise Value
$961.25B$15.57B
Dividend Yield
0.06%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Micron Technology, Inc.

Micron Technology (MU) trades at $925.24, up 7.46% with strong earnings momentum after beating Q1 2026 EPS estimates of $20.98 with $25.11. The stock shows bearish technical signals despite robust fundamentals including 55.91% net margin and 32.62% ROE. Recent news highlights AI-driven memory demand growth but concerns about cyclicality and competitive threats from new entrants like SpaceX's Terrafab facility.

Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target, though technical weakness and memory market cyclicality pose near-term risks. The company's strategic customer agreements provide revenue visibility through 2030, supporting long-term growth potential despite current bearish technical indicators.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.

While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Micron Technology, Inc.

Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.

Read more on MU

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN